Biotechnology cancer Cancer screening

A New Tool to Help Fight an Old Enemy – Lung Cancer

November is Lung Cancer Awareness Month and in the United States, lung cancer remains the leading cause of cancer death among both men and women. The primary reason for high death rates for lung cancer is the fact that this disease is typically detected in very late stages, when treatment is often of little use. In 2011, the National Lung Cancer Screening Trial demonstrated that high-risk smokers who received a
Cancer screening

Doctor-patient discussions neglect potential harms of lung cancer screening, study finds

Although national guidelines advise doctors to discuss the benefits and harms of lung cancer screening with high-risk patients because of a high rate of false positives and other factors, those conversations aren't happening the way they should be, according to a study by researchers from the University of North Carolina Lineberger Comprehensive Cancer Center. Lung cancer screening is recommended for high-risk current and former smokers, but because of the potential
Biotechnology cancer Clinical Trials Uncategorized

Brain metastases common and difficult to treat in ROS1 lung cancer

Increasingly, doctors are treating lung cancer based on the genetic rearrangements driving the disease. For example, cancers that are driven by changes in the genes ALK, EGFR, and ROS1 can now all be paired with drugs that target these specific changes. However, these cancers are not only dangerous in the lung where they appear, but can become especially dangerous if they are able to metastasize to the brain – a
cancer

Biomarker may help diagnose lung cancer earlier

(UPI) -- High levels of a protein found in the bloodstreams of lung cancer patients may lead to a method of detecting the disease earlier, and possibly preventing deaths from it, according to a new study. Researchers found high levels of cytoskeleton-associated protein 4, or CKAP4, in the blood of cancer patients predicted their disease. The research was published Tuesday in the American Journal of Pathology. Lung cancer is the
Biotechnology cancer Cell Therapy

Drug Reduces Size of Some Lung Cancer Tumors, Relapse Rate After Surgery

A drug given to early stage lung cancer patients before they undergo surgery showed major tumor responses in the removed tumor and an increase in anti-tumor T-cells that remained after the tumor was removed, which resulted in fewer relapse cases in the patients. The research teams at the Johns Hopkins Bloomberg~Kimmel Institute for Cancer Immunotherapy, the Johns Hopkins Sidney Kimmel Cancer Center and the Memorial Sloan-Kettering Cancer Center wanted to
cancer Cancer Discovery

Novel Clinical Tool to Predict Patient Survival Rate and Treatment Outcomes for Early-Stage Lung Cancer

A team of researchers, led by Professor Lim Chwee Teck from the Department of Biomedical Engineering at the National University of Singapore (NUS) and NUS PhD candidate Ms Lim Su Bin, has leveraged open source data to develop a personalised risk assessment tool that can potentially predict patient survival rate and treatment outcomes of early-stage lung cancer patients. The tool uses a novel panel of 29 unique extracellular matrix (ECM)
Pharmaceutical Business News

Merck’s Keytruda helps lung cancer patients live longer in trial

Merck & Co's blockbuster drug Keytruda helped previously untreated lung cancer patients live longer in a late-stage trial, potentially cementing its position as the dominant player in the lucrative lung cancer market. Merck is already considered the frontrunner in the space and Keytruda is expected to earn peak sales of over $10 billion in 2023, according to Credit Suisse. Keytruda is already approved in the U.S. to treat patients with
Biotechnology cancer Cancer Discovery Uncategorized

Identifying a New Therapeutic Target for the Most Common Type of Lung Cancer

Research by Rutgers Cancer Institute of New Jersey investigators has identified novel functions of the superoxide dismutase 1 (SOD1) enzyme providing support that it could serve as a therapeutic target in the most common type of lung cancer. Results of the work are being presented as part of a poster session at the American Association for Cancer Research Annual Meeting being held later this week in Chicago. Lung cancer is
Biotechnology cancer Cell Therapy Clinical Trials Immunotherapies

Molecular Inhibitors Can Boost Natural Tumor Suppression to Fight Lung Cancer and Mesothelioma

Inhibition of the oncogenic kinase AKT, a key protein governing the cell cycle, was found to arrest cancer cell proliferation and triggered their programmed death by apoptosis. The study, published today in Oncogene, represents significant progress in the clinical translation of previous basic scientific discoveries. “Understanding the molecular features that govern cancer cell behavior is the basis for the design of the so-called ‘targeted therapies’ which constitute modern precision medicine,”
Cancer Discovery

Thirdhand Smoke Found to Increase Lung Cancer Risk in Mice

Researchers at the Department of Energy’s Lawrence Berkeley National Laboratory (Berkeley Lab) identified thirdhand smoke, the toxic residues that linger on indoor surfaces and in dust long after a cigarette has been extinguished, as a health hazard nearly 10 years ago. Now a new study has found that it also increases lung cancer risk in mice. A team led by Antoine Snijders, Jian-Hua Mao, and Bo Hang of Berkeley Lab
Pharmaceutical Business News

FDA expands approval of Imfinzi to reduce the risk of non-small cell lung cancer progressing

The U.S. Food and Drug Administration today approved Imfinzi (durvalumab) for the treatment of patients with stage III non-small cell lung cancer (NSCLC) whose tumors are not able to be surgically removed (unresectable) and whose cancer has not progressed after treatment with chemotherapy and radiation (chemoradiation). “This is the first treatment approved for stage III unresectable non-small cell lung cancer to reduce the risk of the cancer progressing, when the
Pharmaceutical Business News

Merck KGaA and Pfizer’s Avelumab fails in trial

(Marketwatch) Merck KGaA and Pfizer Inc. said on Thursday that avelumab, a cancer immunotherapy, failed to meet the primary objective of a phase 3 trial in patients with a type of lung cancer. The trial didn't meet the endpoint of improving overall survival in patients whose tumors are PD-L1 positive, the companies said. The Javelin Lung 200 trial compared avelumab to docetaxel, a chemotherapy drug, in patients with advanced non-small-cell
cancer Cancer Discovery

Early Evidence of Efficacy and Safety Seen in Novel Targeted Immunotherapy

An immune-oncology focused biotechnology company, BriaCell, has provided a clinical update on its lead immunotherapy drug for advanced breast cancer. BriaCell provided further update on its ongoing clinical trial of Bria-IMT™ according to Protocol WRI-GEV-007 (listed in ClinicalTrials.gov as NCT03066947).  Six patients have received inoculations since the trial began in early 2017, with the observation that the regimen was well tolerated, had few side effects, and appears safe.   Imaging studies
cancer

Making Milestones Against Non-Small Cell Lung Cancer

 Hard to detect in its early stages and hard to treat as it advances, lung cancer is the leading cause of cancer mortality around the world, with an estimated 1.6 million deaths each year. New treatments, however, are bettering the odds for people with non-small cell lung cancer (NSCLC), which makes up about 85 percent of lung cancer cases. “Progress has been enormous in the past 20 years,” said Roy Herbst,
cancer

Placental Cells Significantly Inhibit Cancer Cell Growth in Newly Published Study

According to the peer-reviewed article in the journal Scientific Reports, placenta-derived cells called PLX cells, exhibit a strong inhibitory effect on various lines of breast, colorectal, kidney, liver, lung, muscle and skin cancers. The research was conducted over more than two years by Pluristem Therapeutics, Inc., a Haifa-based biotechnology company. The article titled “Human Placental-Derived Adherent Stromal Cells Co-Induced with TNF‑a and IFN‑g Inhibit Triple-Negative Breast Cancer in Nude Mouse Xenograft
cancer

Researchers Seek Blood Test for Early Lung Cancer Detection

Researchers at Rush University Medical Center are trying to answer that question by working to develop a blood test for early detection of lung cancer. National Institutes of Health awarded this endeavor a two-year $275,000 grant on Jan. 1. The availability of a simple and cost-effective blood test could change early detection of lung cancer, which is often undiagnosed until symptoms become apparent in a more serious, advanced stage of
Biotechnology cancer Cell Therapy Immunotherapies Prodrug

2-Drug Combination May Boost Immunotherapy Responses in Lung Cancer Patients

Johns Hopkins Kimmel Cancer Center researchers and colleagues have identified a novel drug combination therapy that could prime nonsmall cell lung cancers to respond better to immunotherapy. These so-called epigenetic therapy drugs, used together, achieved robust anti-tumor responses in human cancer cell lines and mice. During the study, published Nov. 30, 2017, in the journal Cell, a team of researchers led by graduate student Michael Topper; research associate Michelle Vaz,
Biotechnology cancer Gene Therapy Prodrug rare diseases

Deadly Lung Cancers Are Driven by Multiple Genetic Changes

Blood-Based Cancer Tests Reveal Complex Genomic Landscape of Non-Small Cell Lung Cancers A new UC San Francisco–led study challenges the dogma in oncology that most cancers are caused by one dominant “driver” mutation that can be treated in isolation with a single targeted drug. Instead, the new research finds one of the world’s most deadly forms of lung cancer is driven by changes in multiple different genes, which appear to
Cancer Discovery

A blood test can predict early lung cancer prognosis

Cancer cells obtained from a blood test may be able to predict how early-stage lung cancer patients will fare, a team from the University of Michigan has shown. This information could be used to determine which patients are most likely to benefit from additional therapies to head off the spread of the cancer to other areas of the body. With a new single cell analysis service in U-M's Comprehensive Cancer
cancer

Research suggests possible new treatment for EGFR-positive lung cancer

Findings from a phase III clinical trial point to a potential new treatment for patients newly diagnosed with advanced, epidermal growth factor receptor (EGFR)-positive non-small cell lung cancer (NSCLC). Compared to the EGFR inhibitor gefitinib (Iressa), one of the standard targeted medicines for this disease, second-generation EGFR inhibitor dacomitinib delayed cancer growth by a median of 5.5 months more. The study was featured in a press briefing and presented at